Penicillin-Streptomycin Treatment Rewires Core Metabolic and Ribosomal Programs in HepG2 Cells
Movassaghi CS., Meyer JG.
Laboratory Study, published in J Proteome Res (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Proteome Res (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41443752
- PMCID
- PMC12888007
- DOI
- 10.1021/acs.jproteome.5c00934
Abstract (original English)
Antibiotics are routinely added to mammalian cell culture media to prevent bacterial growth. However, the use of antibiotics in a cell culture can confound downstream experimental results. While genomic and transcriptomic differences between cell cultures treated with and without antibiotics are well-documented, far fewer, if any, comprehensive proteomic comparisons on the use of antibiotics in cell culture have been performed. Here, we present a study on the proteome-wide differences of culturing HepG2 cells in antibiotic (i.e., penicillin/streptomycin) and nonantibiotic-containing media. Using a longitudinal and crossover treatment study design, we analyzed 119 samples across nine passages and four conditions. On average, 9,374 proteins were detected per sample, and we identified 383 proteins that were differentially abundant between conditions. These changes included ribosomal and mitochondrial proteins, demonstrating that off-target effects of antibiotics on mammalian cells occur at the protein level. Linear mixed-effect modeling suggested that the proteomic impact of antibiotic treatment is strongest in the first passage after treatment and stabilizes after approximately three passages. Furthermore, initiating antibiotic treatment induced a greater number of differentially abundant proteins than discontinuing treatment. Lastly, we compared our results to existing literatur
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.